Novel therapeutic strategies in Parkinson’s disease

Rational drug discovery design approaches for treating Parkinson’s disease

“…Therefore, the inhibitory activity of Neu-120 on glycogen synthase kinase-3b may be an important step toward pharmacological intervention on a relatively exotic potential target site for PD neurotherapeutics. Neu-120 has completed Phase I trials and an ongoing clinical trial is evaluating its efficacy in reducing levodopa-induced dyskinesias in patients with advanced-phase idiopathic PD and motor deficits [69].…”

“…Selective uncompetitive NMDA receptor modulator Inhibits MAO-B Inhibits glycogen synthase kinase 3 b (GSK-3B) I Reduces levodopa-induced dyskinesia Early-to-late PD symptoms Anti-dyskinesia [69] Dipraglurant (ADX48621)…”

“…created from a compilation of information that can be found in[54][55][56][57][58][59][60][61][62][63][64][65][66][67][68][69].…”

PharmGKB summary

“…Unlike other antipsychotics, aripiprazole and bifeprunox act as partial DRD2 agonists. Aplindore, another partial DRD2 agonist, was originally developed as an antipsychotic and is currently being studied as a potential treatment for PD [28,29]. Kapur and Seeman [30] also postulated a fast dissociation hypothesis based on a study of clozapine and quetiapine toward D2 receptor, and suggested that it is the possible explanation for the low extrapyramidal side effects induced by these two drugs as compared with other atypical and typical antipsychotics.…”

Spotlight on opicapone as an adjunct to levodopa in Parkinson’s disease: design, development and potential place in therapy

“…Currently, disease-modifying therapies are not available, and levodopa (LD) treatment remains the gold standard for controlling motor symptoms of the disease 4–7. Nonmotor symptoms (eg, cognitive decline, psychiatric symptoms, autonomic and sleep disturbance, etc) also cause a marked decrease in the quality of life, but currently there is limited evidence that LD treatment can alleviate these symptoms.…”